Epilepsies in children, young people and adults

You can now review and comment on this draft guideline.

The consultation closes at 5pm, 22 December 2021

How to comment

1. Register your organisation or comment as an individual

If you’re commenting for an organisation, your organisation needs to be registered as a stakeholder.

Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your comments to them.

We can accept comments from individuals. These will be considered, but you won’t get a formal response and they won’t be posted on the NICE website. Wherever possible we encourage you to submit your comments through a registered stakeholder organisation.

2. Read the consultation documents

Documents to comment on:

• Draft guideline – just the recommendations

• Evidence reviews
  • NGA Evidence review A  - Yield of MRI
  • NGA Evidence review B  - Yield of CT
  • NGA Evidence review C  - Effectiveness of genetic testing
  • NGA Evidence review D  - Antibody testing in epilepsy
  • NGA Evidence review E  - Monotherapy for generalised tonic-clonic and focal onset seizures
  • NGA Evidence review F  - Monotherapy for generalised tonic-clonic and focal onset seizures
  • NGA Evidence review G  - Antiseizure therapies for absence seizures
  • NGA Evidence review H - Antiseizure therapies for myoclonic seizures
  • NGA Evidence review I   - Antiseizure therapies for tonic or atonic seizures
  • NGA Evidence review J  - Antiseizure therapies for idiopathic generalised epilepsy
  • NGA Evidence review K - Antiseizure therapies for Dravet syndrome
  • NGA Evidence review L  - Antiseizure therapies for Lennox-Gastaut syndrome
  • NGA Evidence review M - Discontinuation of antiseizure medications
  • NGA Evidence review N  - Referral to specialist services 
  • NGA Evidence review O - Effectiveness of an epilepsy nurse specialist
  • NGA Evidence review P  - Antiseizure therapies for infantile spasms
  • NGA Evidence review Q  - Antiseizure medications for centrotemporal spikes
  • NGA Evidence review R  -  Antiseizure therapies for myoclonic atonic epilepsy
  • NGC Evidence review 01 - Second seizure prediction
  • NGC Evidence review 02 - Second seizure modifiable risk factors
  • NGC Evidence review 03 - Diagnosis of epilepsies
  • NGC Evidence review 04 - Information and support
  • NGC Evidence review 05 - Digital health technologies
  • NGC Evidence review 06 - Safety of antiseizure medicines in women and girls
  • NGC Evidence review 07 - Ongoing monitoring
  • NGC Evidence review 08 - Therapeutic drug monitoring in women and girls
  • NGC Evidence review 09 - Antiseizure medication monotherapy and add-on therapies for status epilepticus
  • NGC Evidence review 10 - Antiseizure medication monotherapy and add-on therapies for repetitive or cluster seizures
  • NGC Evidence review 11 - Antiseizure medication monotherapy for prolonged seizures
  • NGC Evidence review 12 - Ketogenic diets for drug-resistant epilepsy
  • NGC Evidence review 13 - Surgery referral and interventions
  • NGC Evidence review 14 - Vagus nerve stimulation
  • NGC Evidence review 15 - Prevalence of psychological disorders
  • NGC Evidence review 16 - Psychological treatments
  • NGC Evidence review 17 - SUDEP prediction
  • NGC Evidence review 18 - Risk Factors for SUDEP
  • NGC Evidence review 19 - Interventions to reduce SUDEP
  • NGC Evidence review 20 - Transition from children’s to adult epilepsy services

• Supplements
  • Supporting documentation NGA Methods 
  • Supporting documentation NGA Health economics 
  • Supporting documentation NGA Health economics - Cost effectiveness of antiseizure therapies
  • Supporting documentation Cochrane abstract - Antiepileptic drug monotherapy for epilepsy NMA  
  • Supporting documentation NGC Health economics Surgery
  • Supporting documentation NGC Methods

If you want to review the economic models, please see 5. Economic models below and fill in the confidentiality form.

Other information about the consultation

• Equality impact assessment
• NGA Committee member list 
• NGC Committee member list
• NGA Team 
• NGA Interests Register
• NGC Acknowledgements
• NGC Interests Register
• Developing NICE guidelines: how to get involved

3. Add your comments

• You must use this comments form.
• You must declare any links with, or funding from, the tobacco industry

If you share similar views with another organisation, send a joint response.

Make sure you consider:

• The areas that will have the biggest impact on practice and be challenging to implement
• How to help users overcome challenges

Developing NICE guidelines: how to get involved suggests some other areas to comment on.

4. Email the form to us

Email: epilepsies@nice.org.uk

Deadline: 5pm, 22 December 2021

5. Economic model

The developers have produced economic models on monotherapy and add-on therapy for focal epilepsy, monotherapy and add-on therapy for generalised tonic-clonic epilepsy, epilepsy specialist nurses and resective surgery to support the guideline on epilepsies in children, young people and adults. To receive executable versions of these models, please submit a request to epilepsies@nice.org.uk with a signed copy of the confidentiality acknowledgement and undertaking form.

We will then send you a link to an executable version of the economic models by email. The deadline for returning your comments is the same as for the guideline consultation: 5pm, 22 December 2021.